TriSalus Life Sciences (NASDAQ:TLSI) Coverage Initiated by Analysts at Northland Securities

Northland Securities assumed coverage on shares of TriSalus Life Sciences (NASDAQ:TLSI - Free Report) in a research report released on Friday morning, MarketBeat Ratings reports. The brokerage issued an outperform rating and a $12.50 price objective on the stock.

TLSI has been the topic of a number of other research reports. Canaccord Genuity Group reiterated a "buy" rating and set a $12.00 price target on shares of TriSalus Life Sciences in a research report on Thursday, June 27th. Oppenheimer started coverage on TriSalus Life Sciences in a research report on Monday, September 16th. They set an "outperform" rating and a $10.00 price target on the stock. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has a consensus rating of "Buy" and an average price target of $12.50.

TriSalus Life Sciences Trading Down 1.0 %

Shares of TLSI stock traded down $0.04 during mid-day trading on Friday, reaching $4.07. The stock had a trading volume of 8,510 shares, compared to its average volume of 38,954. The business's fifty day moving average is $4.74 and its 200-day moving average is $6.43. The firm has a market cap of $119.29 million, a price-to-earnings ratio of -1.63 and a beta of 0.47. TriSalus Life Sciences has a 1-year low of $3.32 and a 1-year high of $10.42.

TriSalus Life Sciences (NASDAQ:TLSI - Get Free Report) last posted its earnings results on Wednesday, August 14th. The company reported ($0.21) EPS for the quarter. The company had revenue of $7.36 million during the quarter. On average, analysts forecast that TriSalus Life Sciences will post -1.53 earnings per share for the current year.

Insider Activity

In related news, CEO Mary T. Szela acquired 7,520 shares of TriSalus Life Sciences stock in a transaction that occurred on Thursday, September 12th. The shares were purchased at an average price of $5.20 per share, for a total transaction of $39,104.00. Following the completion of the transaction, the chief executive officer now owns 377,382 shares in the company, valued at $1,962,386.40. This represents a 0.00 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 32.80% of the company's stock.

Hedge Funds Weigh In On TriSalus Life Sciences

A number of institutional investors have recently added to or reduced their stakes in TLSI. Wolverine Asset Management LLC acquired a new stake in TriSalus Life Sciences during the second quarter worth $240,000. Highbridge Capital Management LLC acquired a new stake in TriSalus Life Sciences during the second quarter worth $1,184,000. Finally, Duquesne Family Office LLC increased its stake in TriSalus Life Sciences by 35.1% during the second quarter. Duquesne Family Office LLC now owns 426,921 shares of the company's stock worth $2,357,000 after acquiring an additional 110,966 shares during the last quarter. Hedge funds and other institutional investors own 2.58% of the company's stock.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.